Seasonal trading patterns in the tnya stock price forecast imply heightened performance in Q4 based on historical cyclical data and industry demand curves. Checking in with the Morgan Stanley view, we find analyst Terence Flynn taking an upbeat view of the company and its prospects for the long-term. Tenaya Therapeutics (NASDAQ: TNYA) , a clinical-stage biotech company focused on developing curative therapies for heart disease, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference . The company's CEO, Faraz Ali , will engage in a fireside chat on Tuesday, August 12, 2025 at 11:30 am ET . With ongoing sector-wide multiple expansion, the tnya stock price forecast incorporates forward P/E gains tied to anticipated margin improvements.